Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U3FP
|
|||
| Former ID |
DIB000612
|
|||
| Drug Name |
Her-2/neu vaccine
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1], [2] | |
| Company |
GlaxoSmithKline
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02336984) A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS. U.S. National Institutes of Health. | |||
| REF 2 | Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010 Jan 15;116(2):292-301. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.